Literature DB >> 18704777

Management of postpartum hemorrhage by uterine balloon tamponade: prospective evaluation of effectiveness.

Stergios K Doumouchtsis1, Aris T Papageorghiou, Chiara Vernier, Sabaratnam Arulkumaran.   

Abstract

OBJECTIVE: To evaluate uterine balloon tamponade in the management of postpartum hemorrhage (PPH). Method and study design. Prospective audit. Setting. St George's Hospital, London. POPULATION: Twenty-seven women with intractable PPH managed by uterine balloon tamponade using a Sengstaken-Blakemore Oesophageal Catheter (SBOC) when medical management was not effective, and prior to surgical intervention. MAIN OUTCOME MEASURES: Success rate of the SBOC in arresting hemorrhage. The need for additional measures, use of anesthesia and complication rates is reported.
RESULTS: During the study period there were 27 women who had placement of the catheter. In 22 cases (81%) hemostasis was achieved, while in five cases (19%) the SBOC failed in arresting hemorrhage. Of the five failures, hysterectomy was required in four cases and in the remaining case the failure was associated with expulsion of the balloon, but hemostasis was achieved with further conservative measures. Among the failed cases there was one maternal death due to amniotic fluid embolism with cardiac arrest and PPH secondary to coagulopathy. In cases where the balloon was successful it was removed around 24 hours later. In these cases no further bleeding was observed, and no complications occurred from the procedure.
CONCLUSIONS: Placement of a SBOC successfully treats atonic PPH refractory to medical management in around 80% of cases. It is simple, inexpensive and in those with successful placement no surgical morbidity was observed. The potential for it to be used by inexperienced operators in areas with limited resources makes it a useful adjunct in management of PPH.

Entities:  

Mesh:

Year:  2008        PMID: 18704777     DOI: 10.1080/00016340802179822

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  7 in total

1.  Prioritizing investments in innovations to protect women from the leading causes of maternal death.

Authors:  Tara M Herrick; Claudia M Harner-Jay; Alice M Levisay; Patricia S Coffey; Michael J Free; Paul D LaBarre
Journal:  BMC Pregnancy Childbirth       Date:  2014-01-09       Impact factor: 3.007

2.  Uterine balloon tamponade in combination with topical administration of tranexamic Acid for management of postpartum hemorrhage.

Authors:  Masato Kinugasa; Hanako Tamai; Mayu Miyake; Takashi Shimizu
Journal:  Case Rep Obstet Gynecol       Date:  2015-03-12

Review 3.  ebb® Complete Tamponade System: effective hemostasis for postpartum hemorrhage.

Authors:  Ross W McQuivey; Jon E Block; Robert A Massaro
Journal:  Med Devices (Auckl)       Date:  2018-03-01

4.  Safety of a condom uterine balloon tamponade (ESM-UBT) device for uncontrolled primary postpartum hemorrhage among facilities in Kenya and Sierra Leone.

Authors:  Aparna Ramanathan; Melody J Eckardt; Brett D Nelson; Moytrayee Guha; Monica Oguttu; Zaid Altawil; Thomas Burke
Journal:  BMC Pregnancy Childbirth       Date:  2018-05-15       Impact factor: 3.007

5.  The application of prophylactic balloon occlusion of the internal iliac artery for the treatment of placenta accreta spectrum with placenta previa: a retrospective case-control study.

Authors:  Ying Peng; Lai Jiang; Cheng Peng; Dabao Wu; Ling Chen
Journal:  BMC Pregnancy Childbirth       Date:  2020-06-08       Impact factor: 3.007

6.  Uterine compression suture is an effective mode of treatment of postpartum haemorrhage.

Authors:  Hongmei Jiang; Li Wang; Jing Liang
Journal:  Pak J Med Sci       Date:  2020 Jan-Feb       Impact factor: 1.088

7.  Cost-effectiveness of uterine tamponade devices for the treatment of postpartum hemorrhage: A systematic review.

Authors:  Joshua P Vogel; Alyce N Wilson; Nick Scott; Mariana Widmer; Fernando Althabe; Olufemi T Oladapo
Journal:  Int J Gynaecol Obstet       Date:  2020-10-30       Impact factor: 3.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.